Ask AI
Atopic dermatitis and IL13 inhibitor patient candidacy
Evidence-Based Care in Atopic Dermatitis: Practical Considerations for IL-13 Inhibitors for Moderate to Severe Disease

Released: June 25, 2025

Expiration: June 24, 2026

Activity

Progress
1
Course Completed

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:

  • Patient candidacy considerations
  • Treatment advancement strategies that go beyond topical therapies
  • The importance of patient-centered care that address patients’ fears and needs
  • A detailed patient case to highlight take home points